Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Treatments for ARDS important for battling COVID-19

As the COVID-19 pandemic continues, pharmaceutical companies are working on finding treatments to lessen the symptoms of the disease. Several drugs are being investigated for their ability to reduce acute respiratory distress syndrome (ARDS), a cause of death in COVID-19 patients. Finding a treatment for this syndrome will play an important role in decreasing the […]
Read more

Branded digital support for rheumatoid arthritis patients in Japan looks competitive and encouraging, says GlobalData

The rheumatoid arthritis (RA) treatment landscape in Japan is highly competitive with many novel disease-modifying anti-rheumatic drugs (DMARDs). To stay ahead of the competition, the branded support offered to RA patients by companies marketing these drugs looks competitive and encouraging, says GlobalData, a leading data and analytics company. According to GlobalData’s report, ‘Rheumatoid Arthritis: Global […]
Read more

Gilead’s remdesivir new standard of care against COVID-19, according to Fauci, but logistics of remdesivir distribution remains unclear

Following the news that Gilead’s antiviral remdesivir has met its primary endpoint in a clinical trial run by the National Institute of Allergy and Infectious Diseases (NIAID) in moderate to severe hospitalized COVID-19 patients and NIAID Director Dr. Fauci describing remdesivir as likely the new standard of care; Philipp Rosenbaum, PhD, Infectious Diseases Analyst at […]
Read more

Dapnat launch to boost Natco’s presence in India’s diabetes market but concerted efforts required, says GlobalData

India-based Natco Pharma has recently launched a generic version of AstraZeneca’s patented anti-diabetes drug Forxiga (dapagliflozin). Natco’s sodium glucose co-transporter-2 (SGLT2) inhibitor, Dapnat, is indicated for the treatment of type 2 diabetes (T2D), and is expected to boost the company’s overall presence within the Indian diabetes market, says GlobalData, a leading data and analytics company. […]
Read more

COVID-19 vaccine timeframe likely to be longer than 12 months

As the COVID-19 pandemic continues, developing a vaccine for the disease becomes a pressing manner, but a reasonable time frame for accomplishing a working vaccine may be longer than 12 months. Considering vaccines typically take years to develop, expectations surrounding the timeframe for a vaccine should be tempered. As COVID-19 therapeutics could be available in […]
Read more

Roche’s Actemra a possible candidate for severe COVID-19 treatment

Roche’s Actemra (tocilizumab) generated $687m in the first quarter of 2020, a 30% increase compared to the same period in 2019, due to evidence of effective treatment in severe COVID-19 patients experiencing respiratory failure. However, Actemra’s Q1 sales increase may be a one-off occurrence as Kevzara fell short in its Phase II trial, says GlobalData, […]
Read more

Disinfectants and UV are not approved for treating COVID-19

Following the news that President Trump discussed in a press conference how UV rays and certain disinfectants may kill the coronavirus, Johanna Swanson, Product Manager at GlobalData, a leading data and analytics company, offers her view: “Disinfectants are in no way an approved treatment for COVID-19, and suggesting their administration via injection, ingestion or other […]
Read more
,

NHS collaborates with leading technology providers to develop COVID-19 response data platform

The National Health Service’s (NHS) data platform will help the country implement a co-ordinated and effective response to the rapidly evolving COVID-19 crisis in the UK, says GlobalData, a leading data and analytics company. Kathryn Whitney, MSc, GlobalData Director of Thematic Analysis, comments: “This data platform will give key decision makers in the NHS real-time […]
Read more

Two-thirds of COVID-19 cases may be undiagnosed

Up to 80% of COVID-19 cases are mild or asymptomatic and therefore unlikely to be diagnosed. Determining what percentage of the population is asymptomatic will allow us to know how close we are to achieving herd immunity for COVID-19 and when it is safe to loosen isolation and quarantine restrictions, says GlobalData, a leading data […]
Read more

Clinical trials evaluating pain and mental health conditions are the neurology indications affected most by COVID-19, says GlobalData

Clinical trials evaluating pain and mental health conditions are the neurology indications most affected by the ongoing COVID-19 pandemic, says GlobalData, a leading data and analytics company. A combination of lockdown measures as well as the need to re-prioritize existing healthcare resources in a hospital setting are all essential steps being taken to combat the […]
Read more

EU’s unity is being tested by COVID-19 outbreak, says GlobalData

The European Union needs more solidarity and coordinated actions to effectively respond to the COVID-19 outbreak, says GlobalData, a leading data and analytics company. Urte Jakimaviciute, MSc, Senior Director of Market Research at GlobalData, commented: “Even though the EU has been implementing various measures to mitigate the consequences of the COVID-19 outbreak, the bloc initially […]
Read more

Gilead’s suspension of Covid-19 trials in China should serve as bellwether for studies in other countries, says GlobalData

Following the news that China trials of Gilead Sciences Inc’s antiviral drug remdesivir in patients with mild symptoms of coronavirus (Covid-19) have been suspended due to lack of eligible patients; Michael Breen PhD, Associate Director of Infectious Diseases at GlobalData, a leading data and analytics company, provides his view:  “As the Covid-19 outbreak becomes controlled, […]
Read more

COVID-19 and post-Brexit immigration system set to worsen NHS staffing crisis

Austerity measures, dissatisfaction with politics, lack of transparency in the EU’s decisions and uncontrolled immigration may have been the major factors influencing the Brexit vote. Nevertheless, constraints on post-Brexit immigration will hurt Britain’s labor market as a large proportion of UK businesses, including the UK’s National Health Service (NHS), rely on an external workforce. The […]
Read more

LabCorp’s at-home COVID-19 test to reduce demand for PPE

Following the Food and Drug Administration’s (FDA) authorization of the first COVID-19 diagnostic test with a home-collection option; Aliyah Farouk, Medical Device Analyst at GlobalData, a leading data and analytics company, offers her view: “GlobalData expects LabCorp’s at-home COVID-19 test to ease demand for much needed personal protective equipment (PPE). Although the test can currently […]
Read more
1 … 96 97 98 99 100 … 110